MedTech Robotics Surgery

Challenges Ahead for Large Format Surgical Robotics

Released on July 20, 2020 | Written by Joe Mullings of The Mullings Group

The news that J&J has decided to change their plans for a 510(k) pathway for it’s Verb-Auris general surgery robot should come as no surprise.

Large format surgical robotics is a damn difficult business.

Must haves:

– A CAPEX mindset when it comes to product development and sales pathway.

– Ongoing and aggressive product development.

– 100% ownership of the product roadmap. JV’s in robotics are near impossible to pull off.

– Deep pockets and a corporate structure that can tolerate large losses in the initial years of development and launch.

The Johnson & Johnson and Medtronic quandary will be an interesting one to watch. Culturally they are both disposable / single use companies and not CAPEX cultures.

Internally, developing and launching large format surgical robotic platforms goes directly against their culture as well as a clear and present threat to their current revenue streams in their portfolios.

Many divergent stakeholders on their buses.

Buying a robotic platform does not make you a robotic culture. Fascinating challenges ahead.

Related Article: J&J drops planned 510(k) for Verb-Auris general surgery robot, targets 2022 clinical trial start

Written by

The Mullings Group